June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
PARP inhibition: Could a target for cancer therapy also be a target for the treatment of Retinitis Pigmentosa?
Author Affiliations & Notes
  • Ayse Sahaboglu
    Division of Experimental Ophthalmology, Institute for Ophthalmic Research, Tübingen, Germany
  • Melanie Barth
    Division of Experimental Ophthalmology, Institute for Ophthalmic Research, Tübingen, Germany
  • Manoj Kulkarni
    Division of Experimental Ophthalmology, Institute for Ophthalmic Research, Tübingen, Germany
  • Francois Paquet-Durand
    Division of Experimental Ophthalmology, Institute for Ophthalmic Research, Tübingen, Germany
  • Footnotes
    Commercial Relationships Ayse Sahaboglu, None; Melanie Barth, None; Manoj Kulkarni, None; Francois Paquet-Durand, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5461. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ayse Sahaboglu, Melanie Barth, Manoj Kulkarni, Francois Paquet-Durand; PARP inhibition: Could a target for cancer therapy also be a target for the treatment of Retinitis Pigmentosa? . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5461.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Poly-ADP-ribosylation (PARylation) is one of the most important post-translational modifications of histone proteins. As such it is involved in many cellular pathways including transcription, DNA repair, and cell death. PARylation is performed by the enzyme poly-ADP-ribose-polymerase (PARP) using NAD+ and antagonized by poly-ADP-ribose-glycohydrolase (PARG) which hydrolyses PAR polymers from acceptor proteins. Currently, several PARP inhibitors are tested clinically for the treatment of different types of cancer. However, excessive PARP activity is also known to be involved in photoreceptor degeneration in various animal models for Retinitis Pigmentosa. Therefore, we investigated the therapeutic potential of clinically used PARP inhibitors on inherited photoreceptor degeneration using in vitro organotypic explant cultures derived from rd1, rd2, and rd10 mice.

Methods: rd1, rd2, rd10, and corresponding wild-type (wt) retinae were analyzed at the peak of degeneration using TUNEL staining for the detection of cell death, PARP in situ activity assay, and PAR immunohistochemistry. Retinal explants derived from wild-type, rd1, rd2,and rd10 animals were cultured under serum free conditions with/without different concentrations of PARP inhibitors PJ34, (A-99) and (R-99).

Results: The TUNEL assay and PAR accumulation showed a significant increase in photoreceptor layers in rd1, rd2, rd10. Retinal explants treated with PARP inhibitors (A-99; R-99) showed a significant decrease in the number of dying cells and in the number of cells showing PAR accumulation, when compared to their untreated counterparts.

Conclusions: Three different animal models for Retinitis Pigmentosa, carrying different mutations all showed an increase in PARP activity and PAR accumulation concomitant with photoreceptor degeneration. The inhibition of PARP protected rd1, rd2, rd10 photoreceptors from mutation-induced cell death suggesting a high therapeutic potential for neuroprotective strategies aimed at inhibiting PARP. The fact that several PARP inhibitors are already in clinical use for the treatment of cancer should facilitate a translation into a treatment for Retinitis Pigmentosa and related inherited diseases of the retina.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×